跳至主要内容
临床试验/NCT02595359
NCT02595359已完成2 期

Intracameral Moxifloxacin for Prevention of Postcataract Endophthalmitis

Universidade Federal de Pernambuco1 个研究点 分布在 1 个国家目标入组 1,000 人开始时间: 2013年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
1,000
试验地点
1
主要终点
endothelial cell count

研究概览

简要总结

The aim of this study was to evaluate the efficacy and safety of the prophylactic effect of intracameral moxifloxacin for prevention of postcataract endophthalmitis.

详细描述

Although cataract surgery is generally considered a safe procedure resulting in a favourable visual outcome, surgical complications do occur. The most feared complication is postoperative endophthalmitis which is an infectious condition caused by micro-organisms introduced to the interior of the eye during or after the surgical procedure.

As endophthalmitis is an infection, it should be preventable by antibiotic treatment.

Prophylactic antibiotic treatment can be given as topical treatment preoperatively, or during surgery directly into the anterior chamber, or as a subconjunctival, or it can be given as topical treatment postoperatively.

The aim of this study was to evaluate the efficacy and safety of the prophylactic effect of intracameral moxifloxacin for prevention of postcataract endophthalmitis.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Prevention
盲法
None

入排标准

年龄范围
50 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosis of visually significant cataract

排除标准

  • Has known allergies to moxifloxacin
  • Has significant ocular co-morbidities in one or both eyes which may include (but is not limited to): advanced glaucoma, advanced or active macular degeneration, Fuchs corneal dystrophy, prior corneal transplantation, advanced diabetic eye disease, history of retinal detachment or any patient that would require billing a complex cataract procedure for any reason
  • Has a known history of a condition which causes an immuno-compromised host state

研究组 & 干预措施

moxifloxacin intracameral

Experimental

moxifloxacin injection given at conclusion of cataract intervention

干预措施: Moxifloxacin (Drug)

结局指标

主要结局

endothelial cell count

时间窗: 6-month; 1 year; 2 years

次要结局

  • endophthalmitis incidence(1 month)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Rodrigo Pessoa Cavalcanti Lira

Professor

Universidade Federal de Pernambuco

研究点 (1)

Loading locations...

相似试验